Amedisys (AMED) & Its Competitors Critical Survey

Amedisys (NASDAQ:AMED) is one of 26 publicly-traded companies in the “MED – OUTP/HM CRE” industry, but how does it compare to its competitors? We will compare Amedisys to related businesses based on the strength of its profitability, institutional ownership, risk, earnings, analyst recommendations, valuation and dividends.

Profitability

This table compares Amedisys and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amedisys	3.79%	12.52%	7.01%
Amedisys Competitors	-12.27%	-0.50%	-4.12%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Amedisys and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amedisys	0	3	1	0	2.25
Amedisys Competitors	108	902	1364	57	2.56

Amedisys currently has a consensus target price of $100.75, indicating a potential upside of 4.42%. As a group, “MED – OUTP/HM CRE” companies have a potential upside of 32.90%. Given Amedisys’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Amedisys has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

94.4% of Amedisys shares are owned by institutional investors. Comparatively, 71.8% of shares of all “MED – OUTP/HM CRE” companies are owned by institutional investors. 2.1% of Amedisys shares are owned by insiders. Comparatively, 9.4% of shares of all “MED – OUTP/HM CRE” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Amedisys and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Amedisys	$2.35 billion	$43.23 million	35.60
Amedisys Competitors	$3.78 billion	$179.91 million	19.15

Amedisys’ competitors have higher revenue and earnings than Amedisys. Amedisys is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Amedisys has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Amedisys’ competitors have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Summary

Amedisys competitors beat Amedisys on 8 of the 13 factors compared.

Amedisys Company Profile

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer’s. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.